Track ATXI and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Main
Market Cap$782.77K
Enterprise Value$3.91M
Revenue (TTM)$1.40M
Net Income (TTM)-$2.91M
Free Cash Flow (TTM)-$1.83M
Financial Health
Cash$2.85M
Net Debt$3.13M
Debt Ratio2.04
Debt to Equity3.27
Interest Coverage-
Valuation (TTM)
Price to Sales0.56
Price to Earnings-0.27
EV to EBITDA-1.21
Price to Book0.43
Price to Free Cash Flow-0.43
Margins (TTM)
Gross Profit Margin0.00%
EBITDA Margin-231.20%
Operating Income Margin-234.12%
Net Income Margin-207.19%
Free Cash Flow Margin-130.56%
Returns (5Y Avg)
Return on Invested Capital-296.63%
Return on Assets-267.88%
Return on Equity-286.04%
Return on Total Capital-296.63%
Return on Capital Employed-673.02%
Dividend Summary
Dividend Yield-
Annual Dividend-
Payout Ratio-
Ex Dividend Date-
5-Year Dividend CAGR-
CAGR (5Y)
Revenue1000.00%
Diluted EPS14.89%
Total Debt0.00%
Capital Expenditures-93.69%
Free Cash Flow9.20%
CAGR (3Y)
Revenue1000.00%
Diluted EPS8.51%
Total Debt0.00%
Capital Expenditures0.00%
Free Cash Flow29.80%
CAGR (1Y)
Revenue1000.00%
Diluted EPS635.34%
Total Debt0.00%
Capital Expenditures0.00%
Free Cash Flow1000.00%
$0.25$0.00|+0.00%
52W High$0.97
52W Low$0.15
50D SMA$0.31
200D SMA$0.48
Volume0.00
Avenue Therapeutics Inc
1111 Kane Concourse, Bay Harbor Islands, FL, United States, 33154
IPO
2017
Employees
1
Industry
Biotechnology
Sector
Healthcare
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include ATX-04, a small molecule therapy for the treatment of Pompe disease; and intravenous tramadol, a schedule IV opioid to treat post-operative acute pain. The company was incorporated in 2015 and is headquartered in Bay Harbor Islands, Florida.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q4 20241-1
0
Analyst Ratings
1 analysts covering
Buy100%recommend buy
Buy
1
Hold
0
Sell
0